Back to mobile site

Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval

October 4, 2017 7:27 AM EDT Send to a Friend
BTIG analyst Timothy Chiang raised his price target on Mylan (NASDAQ: MYL) to $45.00 (from $42.00) while maintaining a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login